Drug profile · INN
mecasermin rinfabate recombinant
IPLEX
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
mecasermin rinfabate recombinant (IPLEX) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
INN mecasermin rinfabate recombinant
Brand IPLEX
Route SUBCUTANEOUS
Formulation INJECTABLE
Frequently asked questions
What is mecasermin rinfabate recombinant?
mecasermin rinfabate recombinant (IPLEX) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for mecasermin rinfabate recombinant?
IPLEX is a marketed brand name for mecasermin rinfabate recombinant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mecasermin rinfabate recombinant?
mecasermin rinfabate recombinant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.